Schrodinger Inc.
06/29/2026 | Press release | Distributed by Public on 06/29/2026 14:29
Regulation FD Disclosure (Form 8-K)
Item 7.01. Regulation FD Disclosure.
In connection with the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc. ("Ajax"), a company co-founded by Schrödinger, Inc. (the "Company"), the Company received a cash payment of approximately $57 million. The Company is also eligible to receive additional cash payments upon the achievement by Ajax of specified clinical and regulatory milestones.
The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Schrodinger Inc. published this content on June 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 29, 2026 at 20:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]